Benefits
Higher Blood Levels Than Unformulated Quercetin (Absorption, Not a Health Outcome)
The Phytosome® delivery system solves quercetin's poor water solubility — the main reason unformulated quercetin shows <2% absorption from food. In a single-dose randomized crossover study in 12 healthy volunteers, funded and authored by the manufacturer, 500 mg of Quercefit® (about 200 mg of quercetin) produced a peak plasma quercetin level about 20 times higher than 500 mg of unformulated quercetin (223 vs 11 ng/mL) and roughly 20 times the total exposure, and the 250 mg dose gave about half those values. A 2025 systematic review from Monash University pooling 31 human quercetin absorption studies also lists the lecithin phytosome at a 20.1-fold increase, though that figure is drawn from this same manufacturer study, so no independent laboratory has repeated the measurement. This translates to meaningful blood quercetin levels at supplemental doses that food simply cannot reach.
Nasal and Eye Allergy Symptoms in One Placebo-Controlled Trial
The only randomized, double-blind, placebo-controlled test is a 4-week Japanese trial in 66 adults with pollen-related symptoms: 200 mg of quercetin as the phytosome daily improved eye itching, sneezing, nasal discharge and sleep disturbance, and quality-of-life scores, against placebo. The asthma numbers usually quoted for this ingredient come from a separate 30-day open registry of 58 patients (30 supplemented, 28 on standard care only) with no placebo, no blinding and no randomization, so the size of that effect is not reliable. Asthma and allergic rhinitis are diagnosed conditions and nothing here replaces prescribed treatment.
Run Time and Recovery in One Unblinded Athlete Registry
Exercise performance and recovery in athletes: in non-professional triathletes, Quercefit® 250 mg twice daily reduced run time from start to finish by 11.3% (vs 3.9% in controls). Post-run muscle pain, cramps and recovery time were rated better and oxidative stress readings fell. This was a 2-week registry of 48 amateur triathletes who were not randomized (23 supplemented, 25 not), there was no placebo and no blinding, several outcomes were self-rated, and two authors work for the manufacturer, so treat it as a starting point rather than proof.
Lower Fatigue Scores in a Double-Blind Trial
In a 2-month double-blind, placebo-controlled trial, 78 adults with a mean age of 56 who reported chronic fatigue took 500 mg/day of quercetin phytosome or placebo. Fatigue Impact Scale scores fell 10.6 points further in the supplement group than in the placebo group, sleep quality and a short physical performance battery improved, and daily step counts rose by about 1,440. This is one trial, two of its authors work for the manufacturer, and no independent group has repeated it.
Antioxidant and Anti-Inflammatory Action
Antioxidant and anti-inflammatory action: quercetin is among the most potent dietary flavonoids for free-radical scavenging and inhibits the NF-κB pathway that drives chronic inflammatory cytokine production. With Quercefit® delivering far more quercetin to the bloodstream, the human measurements so far are limited to biomarkers: oxidative stress readings fell in two unblinded registry studies, and a 3-day study in 57 volunteers found a smaller skin wheal after a histamine injection. Falling oxidative stress readings are laboratory numbers, not a health outcome.
Mast Cell Stabilization and Histamine Modulation
Mast cell stabilization and histamine modulation: quercetin stabilizes mast cells, reducing the degranulation and histamine release that drive allergic responses. In an unblinded 3-day study of 57 healthy volunteers, the wheal and the redness after a histamine injection were smaller in the groups taking 250 mg/day and 500 mg/day than in untreated controls, with the larger dose giving the larger effect. It was published in Esperienze Dermatologiche in 2020 by the same Italian group that ran the asthma registry, it is not indexed in PubMed, the comparison group took nothing, and nobody was blinded.
Small Interaction Check With Blood Thinners and Metformin
One uncontrolled before-and-after study, published in Minerva Cardioangiologica in 2019, tested 62 patients in three groups: bleeding time in 30 people on aspirin, ticlopidine or clopidogrel after 10 days of Quercefit®, INR in 20 people on warfarin or dabigatran after 20 days, and blood glucose plus HbA1c in 12 people with diabetes on metformin after 20 days. None of those measurements changed significantly. There was no control group and no randomization, the groups are small and the exposure was short, so this lowers concern rather than settling it. Anyone taking these medicines should tell their doctor before starting.
Mechanism of action
Phytosome® Bioavailability Enhancement
Quercetin's near-zero oral absorption is driven by its extremely poor water solubility. Complexing quercetin 1:1 with sunflower-derived phosphatidylcholine forms a lipid-soluble Phytosome that crosses the intestinal mucosa much more efficiently. In 12 healthy volunteers, 500 mg of the phytosome complex (about 200 mg of quercetin) raised peak plasma quercetin about 20-fold (223 vs 11 ng/mL) and total exposure roughly 20-fold compared with 500 mg of unformulated quercetin, and the 250 mg dose gave about half those values. The study was run and authored by the manufacturer.
Mast Cell Stabilization
Quercetin inhibits IgE-triggered degranulation of mast cells, reducing the release of histamine, leukotrienes, and other mediators responsible for itching, sneezing, nasal discharge, and bronchoconstriction. The human evidence is one unblinded 3-day study in 57 volunteers in which the skin wheal after a histamine injection was smaller at 250 and 500 mg/day than in untreated controls.
NF-κB Pathway Inhibition
NF-κB is the master transcription factor driving production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. Quercetin inhibits NF-κB nuclear translocation and downstream cytokine production, This pathway work comes from cell and animal experiments. In people, the only inflammation-related readouts reported with this product are oxidative stress markers in unblinded registry studies.
Antioxidant / Free Radical Scavenging
Quercetin's catechol B-ring and 3-hydroxyl group make it one of the more chemically active flavonoid antioxidants, directly neutralizing reactive oxygen species and regenerating other antioxidants like vitamin C and glutathione. Oxidative stress markers improved in the unblinded triathlete registry, consistent with the in vitro free-radical scavenging activity scaling to the bloodstream when bioavailability is enhanced.
Histamine H1 Receptor Antagonism (Modest)
Quercetin shows modest binding affinity at H1 histamine receptors in vitro, adding to its anti-allergic profile beyond mast cell stabilization. The clinical effect is unlikely to approach pharmaceutical antihistamines, but contributes to the multi-mechanism profile that may explain symptomatic improvements observed in allergic rhinitis trials.
Antiviral Activity Seen Only in Laboratory Studies
Quercetin binds several viral targets in test-tube experiments, including the SARS-CoV-2 main protease. Laboratory binding is not a health claim. The COVID-19 studies of quercetin phytosome were open-label trials in patients already receiving medical care for a diagnosed infection, with no placebo and no blinding, and they are not a reason to take a supplement to prevent or treat any illness.
Clinical trials
Single-dose randomized three-way crossover pharmacokinetic study published in European Journal of Drug Metabolism and Pharmacokinetics. There was no placebo group: each volunteer acted as his or her own control, and all five authors are employees of Indena, which makes the ingredient. Compared Quercetin Phytosome® (Quercefit®, batch 06/16/PA) film-coated tablets given as 250 mg and 500 mg of the phytosome complex, which is about 40% quercetin by weight, against 500 mg of unformulated quercetin.
12 healthy adults aged 18 to 50, each receiving all three single doses in randomized order under fasting conditions.
Peak plasma quercetin was about 20 times higher with 500 mg of the phytosome complex than with 500 mg of unformulated quercetin (223 vs 11 ng/mL), and total exposure was about 20 times higher. The 250 mg dose produced about half those values, showing dose proportionality. Note that the 500 mg phytosome arm delivers only about 200 mg of quercetin, so the two arms are not matched on quercetin content. This study measures absorption only. It does not show that any health outcome improves, and it does not support dosing up to 1,000 mg/day, which no arm of it tested.
Open-label pilot registry published in Minerva Medica. Participants were not randomized and there was no placebo: subjects took the supplement alongside standard management or had standard management alone. 30-day intervention comparing Quercefit® 1-2 tablets/day (250-500 mg) plus standard management vs standard management alone, with outcomes assessed via the GINA classification system.
58 adults with mild-to-moderate asthma and allergic rhinitis: 30 took the supplement (20 of them at 200 mg/day quercetin, 10 at 100 mg/day) and 28 had standard management only.
Over 30 days the supplemented group had fewer daytime and nighttime symptoms, higher peak expiratory flow, less use of inhalers, nasal drops and rescue medication, a better rhinitis score and lower oxidative stress readings than the standard-care group. With no randomization, no placebo, no blinding and patient-reported symptom scores, the size of these differences cannot be taken at face value. The authors are the Chieti-Pescara group that has produced most of the published work on this ingredient.
Pilot registry study published in Minerva Medica, with no randomization, no placebo and no blinding. Two of the authors are Indena employees. Fourteen days of Quercefit® 250 mg twice daily (500 mg/day total) versus no supplement, across a training block of eight repeated sprint-distance runs.
48 amateur triathletes: 23 took the supplement and 25 did not.
Improvement in time to complete the run from baseline to day 14 was 11.3% in the supplemented group versus 3.9% in the controls. Post-run muscle pain, cramps and recovery time were rated better with the supplement and oxidative stress readings fell. Because the groups were self-selected rather than randomized and nobody was blinded, and because most of the recovery outcomes were rated by the athletes themselves, this is a preliminary signal from one 2-week study.
Randomized but open-label trial with no placebo, published in Frontiers in Pharmacology in 2023 and registered as NCT04861298, run at King Edward Medical University in Lahore. Patients received standard care plus 500 mg Quercetin Phytosome® three times daily in week one and twice daily in week two, or standard care alone. An interim analysis of the first 42 patients of this same trial was published separately in 2021, so those two papers describe one study, not two.
100 outpatients with mild-to-moderate COVID-19 receiving medical care (50 per group).
After one week, 34 of the 50 patients taking quercetin tested negative for SARS-CoV-2 versus 12 of 50 on standard care alone, 26 versus 12 had their acute symptoms resolve, and serum LDH fell from 407 to 258 U/L in the quercetin group. Nobody was blinded, the control group received no comparable tablet, and several of the authors are affiliated with the manufacturer. These were patients treated by doctors for a diagnosed infection. This is not a basis for using a supplement to prevent or treat COVID-19 or any other illness.
Randomized, double-blind, placebo-controlled parallel-group trial published in European Review for Medical and Pharmacological Sciences in 2022. Four weeks of a supplement providing 200 mg of quercetin as Quercetin Phytosome®, or a matching vehicle, with symptoms scored on the Japanese Rhino-conjunctivitis Quality of Life Questionnaire. The authors are based at a Japanese university and a clinical research group, with no manufacturer employees on the paper.
66 Japanese adults with seasonal and/or perennial allergic symptoms.
Repeated oral Quercefit® reduced eye itching, sneezing, nasal discharge, and sleep disturbance for both seasonal and annual allergens vs placebo. Improved quality of life scores. This is the only double-blind, placebo-controlled allergy trial of this ingredient, it enrolled 66 people aged 22 to 78 with pollen-related symptoms, and no independent group has repeated it.
Uncontrolled before-and-after pilot study published in Minerva Cardioangiologica in 2019. Each participant was measured before and after supplementation, with no control group and no randomization. Evaluated potential interactions of Quercefit® with the antiplatelet agents acetylsalicylic acid, ticlopidine, and clopidogrel; anticoagulants warfarin and dabigatran; and glucose control in stable subjects.
62 patients in three separate groups: 30 on aspirin, ticlopidine or clopidogrel for 10 days, 20 on warfarin or dabigatran for 20 days, and 12 with diabetes on metformin for 20 days.
Quercefit® did not appear to alter the activity of any of the antiplatelet agents tested, had no impact on stable subjects using warfarin or dabigatran, and did not interfere with glycemic control. Bleeding time, INR, blood glucose and HbA1c all stayed at their baseline values. With 62 people in total, no control group and exposures of only 10 to 20 days, this lowers concern about these particular combinations without ruling an interaction out.